The FDA has accepted United Therapeutics' supplemental new drug application for nebulized Tyvaso (treprostinil) to treat idiopathic pulmonary fibrosis, with a decision expected by late April 2027. The filing is backed by phase 3 TETON trial data showing a 111.8 mL improvement in forced vital capacity versus placebo. If approved, Tyvaso would be the first inhaled anti-fibrotic therapy for IPF in the US.
FDA accepted United Therapeutics' Tyvaso IPF sNDA after trials showed a 111.8 mL FVC benefit, with a decision due by late April 2027.
"We're galvanized by the FDA's acceptance of the nebulized Tyvaso sNDA for review and believe the strength and rigor of our TETON clinical program support an approvable application for this differentiated multi-pathway treatment for patients managing this life-threatening disease," Martine Rothblatt, chairperson and chief executive officer at United Therapeutics, said.
The filing was based on combined analyses of the phase 3 TETON-1 and TETON-2 studies, which met the primary efficacy endpoint with nebulized Tyvaso demonstrating statistically significant superiority over placebo for change in absolute forced vital capacity by 111.8 mL (Hodges-Lehmann estimate, 95 percent confidence interval 79.7 to 144.0 mL; p<0.0001) from baseline to week 52. The trials also achieved statistical significance on most key secondary endpoints, including reduced risk of clinical worsening, reduced risk of acute IPF exacerbation, and improvements in percent predicted FVC, K-BILD quality of life, and DLCO.
If approved, nebulized Tyvaso would be the first and only inhaled anti-fibrotic treatment for IPF in the US, expanding United Therapeutics' commercial franchise beyond its current pulmonary arterial hypertension and PH-ILD indications. The company estimates at least 100,000 people in the US live with IPF, a progressive lung-scarring disease that can lead to respiratory failure and death.
TETON-1 enrolled patients in the US and Canada, while TETON-2 enrolled patients internationally. TETON-1 data were presented at the 2026 American Thoracic Society annual meeting, and TETON-2 results were published in The New England Journal of Medicine. Combined results from both studies also appeared in NEJM.
Both the FDA and the European Medicines Agency have granted orphan designation for treprostinil to treat IPF. United Therapeutics has also completed enrollment in TETON-PPF, a global phase 3 study evaluating nebulized Tyvaso in progressive pulmonary fibrosis, with top-line data expected in the second half of 2027.
The sNDA was submitted in June following the positive TETON readouts. The TETON program itself grew out of a post-hoc analysis of the INCREASE study in patients with pulmonary hypertension associated with interstitial lung disease, which suggested nebulized Tyvaso was associated with significant FVC improvement. Eligible patients who completed TETON-1 or TETON-2 could enroll in TETON-OLE, an ongoing open-label extension assessing long-term safety in fibrotic lung disease.
Shares of United Therapeutics have risen 0.9 percent year to date, compared with 0.6 percent growth for the broader industry. The company generates the majority of its revenue from the Tyvaso franchise, which includes both nebulized and dry powder inhalation formulations.
The FDA acceptance moves United Therapeutics one step closer to broadening its Tyvaso franchise into a second major pulmonary disease, with IPF representing a substantial addressable market beyond its current PAH focus. Investors will watch the late-April 2027 PDUFA date and the TETON-PPF readout in the second half of 2027 as the next catalysts.
This article is for informational purposes only and does not constitute investment advice.
